Novo Nordisk的口服硫酸盐将2型糖尿病的主要不利心血管事件风险降低14%:SOUL试验。 Novo Nordisk's oral semaglutide lowers major adverse cardiovascular event risk by 14% in Type 2 diabetics: SOUL trial.

根据SOUL试验的结果,Novo Nordisk的口服血浆素表明,患有2型糖尿病的成年人发生重大不良心血管事件的风险减少了14%。 Novo Nordisk's oral semaglutide has shown a 14% reduction in the risk of major adverse cardiovascular events among adults with type 2 diabetes, according to results from the SOUL trial. 这一调查结果表明,糖尿病患者的心脏健康有潜在好处,支持药物在旨在评估其对心血管风险的总体影响的第三阶段研究中的有效性。 This finding indicates a potential benefit for heart health in diabetic patients, supporting the drug's effectiveness in a Phase 3 study aimed at assessing its overall impact on cardiovascular risk.